ASP5541 + Prednisone + Prednisolone + abiraterone acetate + Adrenocorticotropic hormone
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
Trial Timeline
Jun 19, 2025 → May 31, 2032
NCT ID
NCT07005154About ASP5541 + Prednisone + Prednisolone + abiraterone acetate + Adrenocorticotropic hormone
ASP5541 + Prednisone + Prednisolone + abiraterone acetate + Adrenocorticotropic hormone is a phase 2 stage product being developed by Astellas Pharma for Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07005154. Target conditions include Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Prostate Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07005154 | Phase 2 | Recruiting |
Competing Products
20 competing products in Prostate Cancer